The weight management industry is moving through a major shift as pharmaceutical treatments become an increasingly visible part of obesity care. GLP-1-based medicines have moved from being primarily associated with metabolic disease management to becoming a major category within weight loss treatment, supported by rising obesity prevalence, clinical efficacy, greater awareness, and expanding...